Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Grillo

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphomaN L Berinstein, A J Grillo-López, C A White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapyM S Czuczman, A J Grillo-López, P McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Response criteria for NHL: importance of 'normal' lymph node size and correlations with response ratesA J Grillo-López, B D Cheson, S J Horning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapyM S Czuczman, A J Grillo-López, C A White, et al.
The Journal of Clinical Endocrinology and Metabolism|April 12, 2001
One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal womenA L Friedlander, G E Butterfield, S Moynihan, et al.
ACS Chemical Biology|October 22, 2025
Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine DeaminaseRamkumar Moorthy, Michael J Grillo, Jordan W Baur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatmentT A Davis, A J Grillo-López, C A White, et al.
Revista Espanola De Cardiologia (English Ed.)|July 20, 2014
Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in SpainJuan F Delgado, Juan Oliva, Miguel Llano, et al.
Current Pharmaceutical Biotechnology|January 5, 2002
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphomaA J Grillo-López, B K Dallaire, A McClure, et al.
Current Pharmaceutical Biotechnology|July 27, 2001
Rituximab: the first monoclonal antibody approved for the treatment of lymphomaA J Grillo-López, C A White, B K Dallaire, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphomaN L Berinstein, A J Grillo-López, C A White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapyM S Czuczman, A J Grillo-López, P McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Response criteria for NHL: importance of 'normal' lymph node size and correlations with response ratesA J Grillo-López, B D Cheson, S J Horning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapyM S Czuczman, A J Grillo-López, C A White, et al.
The Journal of Clinical Endocrinology and Metabolism|April 12, 2001
One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal womenA L Friedlander, G E Butterfield, S Moynihan, et al.
ACS Chemical Biology|October 22, 2025
Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine DeaminaseRamkumar Moorthy, Michael J Grillo, Jordan W Baur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatmentT A Davis, A J Grillo-López, C A White, et al.
Revista Espanola De Cardiologia (English Ed.)|July 20, 2014
Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in SpainJuan F Delgado, Juan Oliva, Miguel Llano, et al.
Current Pharmaceutical Biotechnology|January 5, 2002
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphomaA J Grillo-López, B K Dallaire, A McClure, et al.
Current Pharmaceutical Biotechnology|July 27, 2001
Rituximab: the first monoclonal antibody approved for the treatment of lymphomaA J Grillo-López, C A White, B K Dallaire, et al.
Pageof 9